DataMeds AI financials
$3.67−3.67%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|
| Revenue | $1.4M | $10.3M | $9.9M | $17.1M |
| Gross profit | $49.0K | $5.5M | $4.7M | $5.7M |
| Gross margin | 3.6% | 53.8% | 48.0% | 33.3% |
| Operating income | -$4.4M | -$2.0M | -$5.3M | -$2.5M |
| Net income | -$17.8M | -$3.5M | -$5.3M | -$2.5M |
| Net margin | −1308.3% | −33.9% | −53.8% | −14.8% |
| Diluted EPS | $-7.49 | $-6.13 | $-0.65 | $-0.33 |
| EBITDA | -$2.1M | -$1.2M | -$2.9M | -$1.8M |
| Operating cash flow | -$2.2M | -$1.6M | -$2.6M | -$2.2M |
| Free cash flow | -$2.2M | -$1.6M | -$2.6M | -$2.3M |
| Diluted shares | 2.4M | 0.6M | 8.1M | 7.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $314.00 | $1.1M | $3.1M | $5.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $500.0K | $0.00 | $0.00 |
| Total assets | $12.5M | $3.7M | $5.8M | $9.8M |
| Total liabilities | $12.0M | $3.4M | $2.0M | $1.1M |
| Shareholders' equity | $542.4K | $342.9K | $3.8M | $8.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology